Suppr超能文献

国家肺癌筛查试验中有无癌症既往史的患者中用低剂量计算机断层扫描进行肺癌筛查。

Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.

机构信息

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.

出版信息

J Thorac Oncol. 2021 Jun;16(6):980-989. doi: 10.1016/j.jtho.2021.02.003. Epub 2021 Feb 10.

Abstract

INTRODUCTION

Patients with a prior history of cancer (PHC) are at increased risk of second primary malignancy, of which lung cancer is the most common. We compared the performance metrics of positive screening rates and cancer detection rates (CDRs) among those with versus without PHC.

METHODS

We conducted a secondary analysis of 26,366 National Lung Screening Trial participants screened with low dose computed tomography between August 2002 and September 2007. We evaluated absolute rates and age-adjusted relative risks (RRs) of positive screening rates on the basis of retrospective Lung CT Screening Reporting & Data System (Lung-RADS) application, invasive diagnostic procedure rate, complication rate, and CDR in those with versus without PHC using a binary logistic regression model using Firth's penalized likelihood. We also compared cancer type, stage, and treatment in those with versus without PHC.

RESULTS

A total of 4.1% (n = 1071) of patients had PHC. Age-adjusted rates of positive findings were similar in those with versus without PHC (Baseline: PHC = 13.7% versus no PHC = 13.3%, RR [95% confidence interval (CI)]: 1.04 [0.88-1.24]; Subsequent: PHC = 5.6% versus no PHC = 5.5%, RR [95% CI]: 1.02 [0.84-1.23]). Age-adjusted CDRs were higher in those with versus without PHC on baseline (PHC=1.9% versus no PHC = 0.8%, RR [95% CI]: 2.51 [1.67-3.81]) but not on subsequent screenings (PHC = 0.6% versus no PHC = 0.4%, RR [95% CI]: 1.37 [0.99-1.93]). There were no differences in cancer stage, type, or treatment by PHC status.

CONCLUSIONS

Patients with PHC may benefit from lung cancer screening, and with their providers, should be made aware of the possibility of higher cancer detection, invasive procedures, and complication rates on baseline lung cancer screening, but not on subsequent low dose computed tomography screening examinations.

摘要

简介

有癌症既往史(PHC)的患者发生第二原发恶性肿瘤的风险增加,其中肺癌最为常见。我们比较了有 PHC 与无 PHC 患者的阳性检出率和癌症检出率(CDR)的性能指标。

方法

我们对 2002 年 8 月至 2007 年 9 月期间接受低剂量计算机断层扫描检查的 26366 名全国肺癌筛查试验参与者进行了二次分析。我们根据回顾性的 Lung CT Screening Reporting & Data System(Lung-RADS)应用、有创诊断程序率、并发症率和有与无 PHC 患者的 CDR,评估了阳性检出率的绝对检出率和年龄校正后的相对风险(RR)。我们还比较了有与无 PHC 患者的癌症类型、分期和治疗情况。

结果

共有 4.1%(n=1071)的患者有 PHC。有与无 PHC 患者的阳性发现率相似(基线:PHC=13.7%,无 PHC=13.3%,RR[95%置信区间(CI)]:1.04[0.88-1.24];随后:PHC=5.6%,无 PHC=5.5%,RR[95%CI]:1.02[0.84-1.23])。在基线时,有 PHC 患者的年龄校正后的 CDR 高于无 PHC 患者(PHC=1.9%,无 PHC=0.8%,RR[95%CI]:2.51[1.67-3.81]),但在随后的筛查中则不然(PHC=0.6%,无 PHC=0.4%,RR[95%CI]:1.37[0.99-1.93])。有无 PHC 患者的癌症分期、类型和治疗方式无差异。

结论

有 PHC 患者可能受益于肺癌筛查,并且应与他们的医生一起意识到在基线肺癌筛查时更高的癌症检出率、有创程序和并发症发生率的可能性,但在随后的低剂量计算机断层扫描筛查检查中则不然。

相似文献

2
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial.
Ann Intern Med. 2010 Apr 20;152(8):505-12, W176-80. doi: 10.7326/0003-4819-152-8-201004200-00007.
3
Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy?
Eur Radiol. 2021 Jan;31(1):458-467. doi: 10.1007/s00330-020-07026-x. Epub 2020 Jul 29.
4
Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.
Eur Radiol. 2021 Apr;31(4):1956-1968. doi: 10.1007/s00330-020-07275-w. Epub 2020 Sep 30.
5
False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making.
J Med Screen. 2018 Jun;25(2):110-112. doi: 10.1177/0969141317727771. Epub 2017 Sep 20.
7
Effectiveness of Lung-RADS in Reducing False-Positive Results in a Diverse, Underserved, Urban Lung Cancer Screening Cohort.
J Am Coll Radiol. 2019 Apr;16(4 Pt A):419-426. doi: 10.1016/j.jacr.2018.07.011. Epub 2018 Aug 23.
9
Overestimation of screening-related complications in the National Lung Screening Trial.
J Thorac Cardiovasc Surg. 2023 Aug;166(2):336-344.e2. doi: 10.1016/j.jtcvs.2022.10.051. Epub 2022 Nov 14.
10
Early Results of Lung Cancer Screening and Radiation Dose Assessment by Low-dose CT at a Community Hospital.
Clin Lung Cancer. 2017 Sep;18(5):e327-e331. doi: 10.1016/j.cllc.2017.01.011. Epub 2017 Feb 2.

引用本文的文献

1
Limited effect of antibiotic use on the management of pulmonary ground-glass nodules.
Sci Rep. 2025 Mar 20;15(1):9653. doi: 10.1038/s41598-025-93693-z.
3
Deep learning-based detection algorithm for brain metastases on black blood imaging.
Sci Rep. 2022 Nov 14;12(1):19503. doi: 10.1038/s41598-022-23687-8.
4
Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.
Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD013829. doi: 10.1002/14651858.CD013829.pub2.
5
Subsequent Primary Cancer Risk Among 5-Year Survivors of Adolescent and Young Adult Cancers.
J Natl Cancer Inst. 2022 Aug 8;114(8):1095-1108. doi: 10.1093/jnci/djac091.
6
European lung cancer screening: valuable trial evidence for optimal practice implementation.
Br J Radiol. 2022 May 1;95(1133):20200260. doi: 10.1259/bjr.20200260. Epub 2022 Jan 7.
7
Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer.
J Natl Cancer Inst. 2022 Jan 11;114(1):87-96. doi: 10.1093/jnci/djab138.

本文引用的文献

1
Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy?
Eur Radiol. 2021 Jan;31(1):458-467. doi: 10.1007/s00330-020-07026-x. Epub 2020 Jul 29.
2
Life-Gained-Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening.
Ann Intern Med. 2019 Nov 5;171(9):623-632. doi: 10.7326/M19-1263. Epub 2019 Oct 22.
3
Patient-Level Trajectories and Outcomes After Low-Dose CT Screening in the National Lung Screening Trial.
Chest. 2019 Nov;156(5):965-971. doi: 10.1016/j.chest.2019.06.016. Epub 2019 Jul 5.
4
Cancer treatment and survivorship statistics, 2019.
CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.
5
Variable impact of prior cancer history on the survival of lung cancer patients.
Lung Cancer. 2019 Jan;127:130-137. doi: 10.1016/j.lungcan.2018.11.040. Epub 2018 Nov 30.
7
Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
Clin Lung Cancer. 2017 Sep;18(5):543-550.e3. doi: 10.1016/j.cllc.2017.02.007. Epub 2017 Mar 2.
8
Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
PLoS Med. 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr.
9
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
Br J Cancer. 2017 Mar 14;116(6):717-725. doi: 10.1038/bjc.2017.27. Epub 2017 Feb 14.
10
Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
Lung Cancer. 2016 Aug;98:106-113. doi: 10.1016/j.lungcan.2016.05.029. Epub 2016 May 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验